Xin Zhang

Wuhan Neurophth Biotechnology Co., Ltd. is a leading in-vivo gene therapy company for ophthalmic diseases based in Wuhan, China. The Chinese company's core product, nr082 (nfs-01), is designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) and has been granted orphan drug designation (ODD) by the FDA and EMA. It is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by the Chinese National Medical Products Administration (NMPA) and the FDA. The company's pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy, and other preclinical candidates. The company was founded in 2016 by Bin Li, Su Xiao, Dabo Cai, and Bin Li has been the CEO since then.